Daiichi Sankyo Subsidiary Submits NDA For Alzheimer's Disease Drug In Japan
This article was originally published in PharmAsia News
Daiichi Sankyo subsidiary Asubio Pharma submitted an NDA for SUN Y7017 (memantine) for Alzheimer's disease in Japan. An N-methyl-D-aspartate receptor antagonist developed by German firm Merz Pharmaceuticals, memantine was approved by the European Medicines Agency in 2002 and by U.S. FDA in 2003.The drug is now marketed in over 60 countries. Developed by Asubio in Japan, memantine will be marketed by Daiichi Sankyo upon approval. (Click here for more - Japanese language
You may also be interested in...
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% during COVID-19 emergency measures as the UK tries to increase supplies
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.